Methods for Identifying Subjects With an Increased Likelihood of Responding to DPP-IV Inhibitors

• US 20110152340A1
• Filed: 05/18/2009
• Published: 06/23/2011
• Est. Priority Date: 05/16/2008
• Status: Abandoned Application

• Current Assignee: Astrazeneca AB (Astrazeneca PLC)
• Original Assignee: Bristol-Myers Squibb Company
• Inventors: Ranade, Koustubh, Simonsen, Katy Lynn Moore, DelMonte, Terrye Aigeldinger, Rodriguez, Lisa Renee, Emison, Eileen
• Application Number:
  US12/990,362
• Publication Number:
  US 20110152340A1
• Time in Patent Office: Days
• US Class Current: 514/412
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C12Q 1/37 involving peptidase or proteinase
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: G01N 2800/042 Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

The invention provides novel in vitro diagnostic methods for identifying subjects or patients who may have an increased likelihood of responding to DPP-IV inhibitor therapy. The invention also provides novel polynucleotides associated with increased responsiveness of a patient to DPP-IV inhibition. Polynucleotide fragments which comprise at least one polymorphic locus, are also provided. Allele-specific primers and probes which hybridize to these polymorphic regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the invention are useful in phenotype correlations, medicine, and genetic analysis.

Claims

1. A method comprising the steps of

(a) assaying a sample from an individual with Type 2 diabetes and

(b) detecting a reference or a variant allele at one or more polymorphic loci of SEQ ID NOs:

1-12, 63, and/or 69-75.

2. The method according to claim 1, wherein said polymorphic loci are at nucleotide position 87,712 of SEQ ID NOs:

1, 73 and/or 75, nucleotide position 87,992 of SEQ ID NOs;

1, 2 and/or 75, nucleotide position 89,441 of SEQ ID NOs;

1, 69 and/or 75, nucleotide position 89,662 of SEQ ID NOs;

1, 70 and/or 75, nucleotide position 89,853 of SEQ ID NOs;

1, 71 and/or 75, nucleotide position 93,598 of SEQ ID NOs;

1, 74 and/or 75, and nucleotide position 94,074 of SEQ ID NOs;

1, 72 and/or 75.

3. The method according to claim 1, wherein said reference allele at the polymorphic locus at nucleotide position 87,712 is “

A” and

said variant allele at the polymorphic locus is “

G”

, wherein said reference allele at the polymorphic locus at nucleotide position 87,992 is “

T” and

said variant allele at the polymorphic locus is “

C”

, wherein said reference allele at the polymorphic locus at nucleotide position 89,441 is “

A” and

said variant allele at the polymorphic locus is “

G”

, wherein said reference allele at the polymorphic locus at nucleotide position 89,662 is “

G” and

said variant allele at the polymorphic locus is “

A”

, wherein said reference allele at the polymorphic locus at nucleotide position 89,853 is “

G” and

said variant allele at the polymorphic locus is “

A”

, wherein said reference allele at the polymorphic locus at nucleotide position 93,598 is “

G” and

said variant allele at the polymorphic locus is “

A”

, and wherein said reference allele at the polymorphic locus at nucleotide position 94,074 is “

G” and

said variant allele at the polymorphic locus is “

C”

.

4. The method of claim 1, wherein the step of assaying a sample from an individual with Type 2 diabetes consists of:

(a) obtaining a nucleic acid sample from said individual; and

(b) subjecting the sample to genetic sequencing, microarray, or PCR analysis to identify the reference or variant allele.

5. The method of claim 1, wherein the step of detecting a reference or a variant allele consists of:

(a) subjecting the sample to automated genetic sequencing;

(b) displaying sequencing data on a data screen for analysis; and

(c) recording the identity of said reference or variant allele at one or more polymorphic loci of SEQ ID NOs;

1-12, 63, and/or 69-75.

6. The method of claim 1, wherein the step of detecting a reference or a variant allele consists of:

(a) obtaining sequence data from the assaying step; and

(b) recording the identity of said reference or variant allele at one or more polymorphic loci of SEQ ID NOs;

1-12, 63, and/or 69-75.

7. The method of claim 5 or 6, further comprising the steps of:

(a) incorporating the identified reference or variant allele data at one or more polymorphic loci of SEQ ID NOs;

1-12, 63, and/or 69-75 into an ANCOVA analysis;

(b) conducting said ANCOVA analysis; and

(c) determining the probability of a favorable response or the magnitude of a favorable change in HbA1C of said individual resulting from treating said individual with a DPP-IV inhibitor or a DPP-IV inhibitor in combination with other oral antidiabetic therapy.

8. The method of claim 5 or 6, further comprising the step of determining the probability of a favorable response or the magnitude of a favorable change in HbA1C of said individual resulting from treating said individual with a DPP-IV inhibitor or a DPP-IV inhibitor in combination with other oral antidiabetic therapy.

9. The method of claim 7 or 8, further comprising the step of administering a DPP-IV inhibitor or a DPP-IV inhibitor in combination with other oral antidiabetic therapy to said individual where said individual is determined to have a probability of a favorable response or a significantly higher magnitude of favorable change in HbA1C resulting from treating said individual with a DPP-IV inhibitor or a DPP-IV inhibitor in combination with other oral antidiabetic therapy.

14. The method of claim 7 or 8, wherein said probability of likelihood of a favorable or said significantly high magnitude of a favorable change in HbA1C response to administration of a DPP-IV inhibitor or a DPP-IV inhibitor in combination with other oral antidiabetic therapy is:

greater in individuals homozygous for reference alleles at one or more polymorphic loci of SEQ ID NOs;

1-12, 63, and/or 69-75;

lower in individuals heterozygous for variant alleles at one or more polymorphic loci of SEQ ID NOs;

1-12, 63, and/or 69-75; and

lower in individuals homozygous for variant alleles at one or more polymorphic loci of SEQ ID NOs;

1-12, 63, and/or 69-75.

10. A method of treating an individual with Type 2 diabetes comprising the steps of:

(a) obtaining a nucleic acid sample from said individual;

(b) subjecting the sample to genetic sequencing, microarray, or PCR analysis;

(c) displaying sequencing data on a data screen for analysis;

(d) recording the identity of said reference or variant allele at one or more polymorphic loci of SEQ ID NOs;

1-12, 63, and/or 69-75;

(e) incorporating the identified reference or variant allele data at one or more polymorphic loci of SEQ ID NOs;

1-12, 63, and/or 69-75 into an ANCOVA analysis;

(f) conducting an ANCOVA analysis of said reference or variant allele data;

(g) determining a probability of the likelihood of a favorable response or the magnitude of a favorable change in HbA1C of said individual resulting from treating said individual with a DPP-IV inhibitor or a DPP-IV inhibitor in combination with other oral antidiabetic therapy; and

(h) administering a DPP-IV inhibitor or a DPP-IV inhibitor in combination with other oral antidiabetic therapy to said individual where said individual is determined to have a high probability of likelihood of a favorable response or a significantly high magnitude of a favorable change in HbA1C resulting from treatment of said individual with a DPP-IV inhibitor or a DPP-IV inhibitor in combination with other oral antidiabetic therapy.

12. The method of claim 9, 10, or 11, wherein said DPP-IV inhibitor is saxagliptin.

13. The method of claim 9, 10, or 11, wherein said other oral antidiabetic therapy is metformin, TZD, or glyburide.

15. The method of claim 10 or 11, wherein said probability of likelihood of a favorable or said significantly high magnitude of a favorable change in HbA1C response to administration of a DPP-IV inhibitor or a DPP-IV inhibitor in combination with other oral antidiabetic therapy is:

greater in individuals homozygous for reference alleles at one or more polymorphic loci of SEQ ID NOs;

1-12, 63, and/or 69-75;

lower in individuals heterozygous for variant alleles at one or more polymorphic loci of SEQ ID NOs;

1-12, 63, and/or 69-75; and

lower in individuals homozygous for variant alleles at one or more polymorphic loci of SEQ ID NOs;

1-12, 63, and/or 69-75.

11. A method of treating an individual with Type 2 diabetes comprising the steps of:

(a) obtaining a nucleic acid sample from said individual;

(b) subjecting the sample to sequence analysis;

(d) recording the identity of said reference or variant allele at one or more polymorphic loci of SEQ ID NOs;

1-12, 63, and/or 69-75;

(e) determining a probability of the likelihood of a favorable response or the magnitude of a favorable change in HbA1C of said individual resulting from treating said individual with a DPP-IV inhibitor or a DPP-IV inhibitor in combination with other oral antidiabetic therapy; and

(f) administering a DPP-IV inhibitor or a DPP-IV inhibitor in combination with other oral antidiabetic therapy to said individual where said individual is determined to have a high probability of likelihood of a favorable response or a significantly high magnitude of a favorable change in HbA1c resulting from treatment of said individual with a DPP-IV inhibitor or a DPP-IV inhibitor in combination with other oral antidiabetic therapy.

16. A diagnostic kit for identifying a subject or patient more likely to have a favorable response to the administration of a therapeutically-effective amount of a DPP-IV inhibitor or a DPP-IV inhibitor in combination with other oral antidiabetic therapy, wherein said kit comprises:

oligonucleotides having SEQ ID NOs;

13-44, 65-66, and 76-103.